ETF aims to develop elderly specific trials for those patients who are not candidates for standard treatment. This will be accomplished in collaboration with the EORTC disease orientated groups. Collaborations with the EORTC Breast Cancer, Lung Cancer, Leukemia, Gastrointestinal Tract Cancer, and Brain Tumor Groups have been established. Collaboration with the Quality of Life Group continues in the validation of an elderly specific quality of life questionnaire.
Outside the EORTC
For geriatric assessment, close collaboration is ongoing with the French geriatric cancer units who developed the G8 screening tool.
National groups in which several ETF members are actively involved will also be contacted for support of clinical trials.
Hans Wildiers, the ETF chairman from 2009 until 2015, has been appointed in 2010 as EORTC representative in the geriatric expert group of the EMA. This expert group is currently working on a uniform frailty tool that can/should be integrated for older individuals in all drug clinical trials in the future.